Genmab — Oktober 2017
-
Vi kommer sikkert under 1300 i dag... god købsmulighed!

-
JKY - Dara er helt sikkert "On track", men markedet er forvirret over at det ikke går snorlige. Man savner forklaring på især ROW. Det er så spørgsmålet om det overhovedet er rimeligt at forlange snorlige tal i regnearket så tidligt i forløbet, hvor vi trods alt fortsat befinder os.
-
Morphosys: Breakthrough therapy status boosts shares to 3-yr high - Reuters News
24-Oct-2017 10:34:59
** Shares of German biotech firm Morphosys's MORG.DE are up 7.5 pct
** Co's antibody MOR208 in relapsed/refractory DLBCLBL gets breakthrough therapy designation from U.S. FDA
** The designation is to speed up the development of co's most advanced blood cancer drug candidate MOR208 in combination with cancer drug lenalidomide, MorphoSys says -
Hvem er AU helt præcist?
-
Tak... så er udsalget igang (der er sikkert en del stop-loss på 1300, som er aktiveret nu)
-
Der er stadig et godt stykke op til fx d. 17. og 18., men det kan jo nå at ændre sig i løbet af dagen.
-
ja der er kø ved udgangen igen igen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind